Fig. 2

Tracer uptake and correlation with immunohistochemical staining and response. a Correlation between SUV_peak for ⁸⁹Zr-nivolumab and ¹⁸F-BMS-986192. R_s = 0.68, p < 0.0001 as determined by the Spearman rank correlation. b Low uptake of the ¹⁸F-BMS-986192 in an untreated brain metastasis in patient 4, due to PD-L1 expression heterogeneity or low CNS penetration of the tracer. c ¹⁸F-BMS-986192 SUV_peak is higher in patients with ≥50% tumor PD-L1 expression. p-value is 0.018, as determined by the Mann–Whitney U-test. d Lesions with no PD-1 expression in aggregates have a lower ⁸⁹Zr-nivolumab SUV_peak. p-value is 0.03, as determined by the Mann–Whitney U-test. e Waterfall plot of the best objective response according to RECIST 1.1. f SUV_peak of the ¹⁸F-BMS-986192 tracer is higher in responding lesions as compared to non-responding lesions (comparison of lesions with diameter of 20 mm or more). p-value is 0.02, as determined by the Mann–Whitney U-test. g SUV_peak of the ⁸⁹Zr-nivolumab tracer is numerically higher in responding lesions (comparison of lesions with diameter of 20 mm or more). p-value is 0.019, as determined by the Mann–Whitney U-test. For all the boxplots, the lower edge of the box represents the first quartile and the upper edge represents the third quartile. The horizontal line inside the box indicates the median. Whiskers identify the minimum and the maximum value